191 related articles for article (PubMed ID: 11564080)
21. [Treatment of B-cell lymphoma with a chimeric anti-CD20 monoclonal antibody(rituximab)].
Tobinai K
Nihon Rinsho; 2002 Jan; 60(1):95-9. PubMed ID: 11808346
[TBL] [Abstract][Full Text] [Related]
22. Correspondence re: T. Davis et al., therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res., 5: 611-615, 1999.
Grillo-López AJ; Kunkel L
Clin Cancer Res; 2000 Jan; 6(1):317-8. PubMed ID: 10656464
[No Abstract] [Full Text] [Related]
23. Recurrent B-cell neoplasms after Rituximab therapy: an immunophenotypic and genotypic study.
Chu PG; Chen YY; Molina A; Arber DA; Weiss LM
Leuk Lymphoma; 2002 Dec; 43(12):2335-41. PubMed ID: 12613521
[TBL] [Abstract][Full Text] [Related]
24. Phase 1 study of interleukin-12 in combination with rituximab in patients with B-cell non-Hodgkin lymphoma.
Ansell SM; Witzig TE; Kurtin PJ; Sloan JA; Jelinek DF; Howell KG; Markovic SN; Habermann TM; Klee GG; Atherton PJ; Erlichman C
Blood; 2002 Jan; 99(1):67-74. PubMed ID: 11756154
[TBL] [Abstract][Full Text] [Related]
25. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
[TBL] [Abstract][Full Text] [Related]
26. CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.
Massengale WT; McBurney E; Gurtler J
J Am Acad Dermatol; 2002 Mar; 46(3):441-3. PubMed ID: 11862185
[TBL] [Abstract][Full Text] [Related]
27. [Clinical observation of Rituximab in a CD20+B non-Hodgkin's lymphoma].
Hao LC; Zhang LZ
Zhonghua Er Ke Za Zhi; 2003 Aug; 41(8):627. PubMed ID: 14744396
[No Abstract] [Full Text] [Related]
28. A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
Foran JM; Gupta RK; Cunningham D; Popescu RA; Goldstone AH; Sweetenham JW; Pettengell R; Johnson PW; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner AZ; Lister TA
Br J Haematol; 2000 Apr; 109(1):81-8. PubMed ID: 10848785
[TBL] [Abstract][Full Text] [Related]
29. Lymphoid aggregates in bone marrow mimic residual lymphoma after rituximab therapy for non-Hodgkin lymphoma.
Douglas VK; Gordon LI; Goolsby CL; White CA; Peterson LC
Am J Clin Pathol; 1999 Dec; 112(6):844-53. PubMed ID: 10587708
[TBL] [Abstract][Full Text] [Related]
30. Immunotherapy with anti-CD20 compounds.
von Schilling C
Semin Cancer Biol; 2003 Jun; 13(3):211-22. PubMed ID: 12959352
[TBL] [Abstract][Full Text] [Related]
31. CD20-negative DLBCL transformation after rituximab treatment in follicular lymphoma: a new case report and review of the literature.
Alvaro-Naranjo T; Jaén-Martínez J; Gumá-Padró J; Bosch-Príncep R; Salvadó-Usach MT
Ann Hematol; 2003 Sep; 82(9):585-8. PubMed ID: 12898184
[TBL] [Abstract][Full Text] [Related]
32. Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates.
Law CL; Cerveny CG; Gordon KA; Klussman K; Mixan BJ; Chace DF; Meyer DL; Doronina SO; Siegall CB; Francisco JA; Senter PD; Wahl AF
Clin Cancer Res; 2004 Dec; 10(23):7842-51. PubMed ID: 15585616
[TBL] [Abstract][Full Text] [Related]
33. Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.
Rufener GA; Press OW; Olsen P; Lee SY; Jensen MC; Gopal AK; Pender B; Budde LE; Rossow JK; Green DJ; Maloney DG; Riddell SR; Till BG
Cancer Immunol Res; 2016 Jun; 4(6):509-19. PubMed ID: 27197068
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibody FMC7 detects a conformational epitope on the CD20 molecule: evidence from phenotyping after rituxan therapy and transfectant cell analyses.
Serke S; Schwaner I; Yordanova M; Szczepek A; Huhn D
Cytometry; 2001 Apr; 46(2):98-104. PubMed ID: 11309819
[TBL] [Abstract][Full Text] [Related]
35. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
36. Intestinal lymphoma perforations as a consequence of highly effective anti-CD20 antibody therapy.
Kollmar O; Becker S; Schilling MK; Maurer CA
Transplantation; 2002 Feb; 73(4):669-70. PubMed ID: 11889454
[No Abstract] [Full Text] [Related]
37. Enhancement of anti-lymphoma immuno-effects mediated by dendritic cells pulsed with heat-stressed and rituximab-coated CD20+ lymphoma cells.
Ai L; Ren H; Shi Y; Dong Y
Int J Hematol; 2008 Jun; 87(5):459-466. PubMed ID: 18414983
[TBL] [Abstract][Full Text] [Related]
38. Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
Palanichamy A; Jahn S; Nickles D; Derstine M; Abounasr A; Hauser SL; Baranzini SE; Leppert D; von Büdingen HC
J Immunol; 2014 Jul; 193(2):580-586. PubMed ID: 24928997
[TBL] [Abstract][Full Text] [Related]
39. CD3 and CD20 Immunohistochemical Staining Patterns of Bone Marrow-Infiltrating Malignant Lymphoma Cells.
Lee EJ; Kim M; Kim HS; Kang HJ; Kim HJ; Min SK; Lee YK
Ann Clin Lab Sci; 2017 Mar; 47(2):136-143. PubMed ID: 28442514
[TBL] [Abstract][Full Text] [Related]
40. Treatment of Human B-Cell Lymphomas Using Minicircle DNA Vector Expressing Anti-CD3/CD20 in a Mouse Model.
Pang X; Ma F; Zhang P; Zhong Y; Zhang J; Wang T; Zheng G; Hou X; Zhao J; He C; Chen ZY
Hum Gene Ther; 2017 Feb; 28(2):216-225. PubMed ID: 27802782
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
